BiomX Receives Approval for NYSE Compliance Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Newsfilter
- Compliance Plan Approval: BiomX received notification from NYSE on June 10, 2026, confirming acceptance of its compliance plan, which is set to last until September 25, 2027, aimed at regaining compliance with NYSE listing standards and ensuring continued trading of its stock on NYSE American.
- Financial Warning: The company reported a stockholders' equity deficit of $1.302 million as of December 31, 2025, alongside ongoing losses over the past five fiscal years, prompting NYSE to require corrective actions for compliance restoration.
- Periodic Review Mechanism: During the implementation of the compliance plan, NYSE will conduct periodic reviews of BiomX's compliance, which not only tests the company's management capabilities but also impacts its future market performance and investor confidence.
- Business Operations Unaffected: Despite facing compliance challenges, BiomX stated that its business operations and reporting obligations to the SEC will remain unaffected, indicating that the company will maintain normal operations while addressing compliance issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHGE
Wall Street analysts forecast PHGE stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.536
Low
26.00
Averages
26.00
High
26.00
Current: 0.536
Low
26.00
Averages
26.00
High
26.00
About PHGE
BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BiomX Receives Approval for NYSE Compliance Plan
- Compliance Plan Approval: BiomX received notification from NYSE on June 10, 2026, confirming acceptance of its compliance plan, which is set to last until September 25, 2027, aimed at regaining compliance with NYSE listing standards and ensuring continued trading of its stock on NYSE American.
- Financial Warning: The company reported a stockholders' equity deficit of $1.302 million as of December 31, 2025, alongside ongoing losses over the past five fiscal years, prompting NYSE to require corrective actions for compliance restoration.
- Periodic Review Mechanism: During the implementation of the compliance plan, NYSE will conduct periodic reviews of BiomX's compliance, which not only tests the company's management capabilities but also impacts its future market performance and investor confidence.
- Business Operations Unaffected: Despite facing compliance challenges, BiomX stated that its business operations and reporting obligations to the SEC will remain unaffected, indicating that the company will maintain normal operations while addressing compliance issues.
See More
BiomX Unveils New Insights on Security Industry
- Industry Transformation: BiomX's Zorronet CEO Idan Wasserman emphasizes in a new review that the future of AI security systems will hinge not on the number of surveillance devices but on their ability to understand information, thereby enhancing responses to complex security environments.
- Cultural Context Understanding: The review highlights that AI systems must grasp cultural and situational contexts to accurately assess the significance of behaviors, preventing misjudgments and ensuring security teams can swiftly respond to genuine threats, thus improving overall security efficiency.
- Increased Control Room Burden: As information sources diversify, traditional control rooms are under growing pressure; Wasserman argues that next-generation security platforms must support real-time prioritization and decision-making to tackle complex security challenges effectively.
- Innovative Technology Integration: Zorronet is developing an Autonomous Command Center designed to unify cameras, sensors, drones, and AI agents into a cohesive real-time operational picture, thereby enhancing the speed and coordination of responses for security and operations teams.
See More
BiomX Appoints Prof. Gabby Sarusi as Strategic Advisor
- Strategic Advisor Appointment: BiomX has appointed Prof. Gabby Sarusi as a Strategic Advisor, leveraging his extensive experience in technology development and strategic planning to enhance the company's expansion in defense and security sectors, thereby improving its market competitiveness.
- Industry Background: Prof. Sarusi brings 17 years of senior leadership experience from Elbit Systems Electro-Optics, where he was involved in developing technologies such as satellite cameras and infrared detectors, providing valuable industry insights for BiomX's integration in critical infrastructure and first-response sectors.
- Market Alignment: Prof. Sarusi noted that the defense and security market is moving towards earlier threat detection and faster response capabilities, aligning perfectly with BiomX's technologies, which are expected to enhance the company's ability to address emerging threats effectively.
- Academic and Practical Integration: With dual bachelor's degrees in Nuclear Engineering and Materials Engineering, along with a master's and Ph.D. in Electrical Engineering, and research experience at NASA and AT&T Bell Labs, Prof. Sarusi's academic background will strongly support BiomX's technological innovation and market application.
See More
BiomX Expands Zorronet's Autonomous C5ISR Suite for Secure Deployments
- Growing Market Demand: BiomX has announced the expansion of Zorronet's autonomous C5ISR suite to support fully secure local, hybrid, and closed-loop deployments in defense, security, and critical infrastructure, reflecting the increasing demand for autonomous command-and-control systems, with the market projected to reach $189 billion by 2030.
- Data Security Protection: The new system allows organizations to run the complete Zorronet C5ISR suite within protected infrastructure, avoiding reliance on public cloud, thereby meeting regulatory and cybersecurity requirements and ensuring that sensitive data remains shielded from public networks.
- Real-Time Response Capability: Zorronet's architecture supports local AI processing and edge computing, enabling real-time inference within restricted networks, which helps teams swiftly transition from detection to execution, significantly enhancing response speed and operational efficiency.
- Integration Advantages: The system can integrate with existing security devices, including cameras, sensors, and drones, forming a unified C5ISR suite that transforms complex security data into clear real-time alerts and commands, thereby improving operational efficiency.
See More
BiomX Successfully Deploys Zorronet with Israel Railways
- Successful Pilot Project: Israel Railways invested approximately NIS 800,000 in the Zorronet pilot project, achieving a 98% success rate in preventing wildlife from entering railway tracks, thereby preserving ecological corridors and reducing infrastructure damage.
- Technical Deployment Details: Zorronet will install 15 AI-enabled alert stations capable of detecting and deterring animals within a 120-meter range, with an initial 12-month agreement and plans for additional stations to enhance railway safety.
- Real-Time Monitoring Capability: The system integrates camera analytics and AI technology to detect human and animal approaches to tracks in real time, quickly assess risks, and trigger alerts, ensuring the safety and efficiency of railway operations.
- Strategic Partnership Outlook: The collaboration with Israel Railways validates Zorronet's position as a technology provider for national infrastructure, with potential for broader deployment across the railway network, further enhancing its competitive edge in the market.
See More
BiomX Acquires DFSL to Expand into Defense Sector
- Acquisition of Control: BiomX Inc. announced the acquisition of a controlling interest in DFSL as part of its expansion into the defense sector, with the deal involving cash payment, an unsecured convertible note, and warrants exercisable at $12 per share, indicating a strategic move into new markets.
- Technology Integration: This month, BiomX also acquired Zorronet, integrating its AI-driven platform for fast and accurate target detection, which reduces false alarms and enhances the company's competitiveness in defense technology.
- DFSL's Expertise: DFSL specializes in hardware and signal processing, having developed LADAR (laser detection and ranging) technology for real-time tracking of aerial or ground targets, thereby strengthening BiomX's technical capabilities in defense applications.
- Stock Price Fluctuation: BiomX closed at $2.63 on Monday, down 9%, but shares rebounded to $2.68 in the overnight market, up 1.90%, reflecting cautious market sentiment regarding the acquisition news.
See More
BiomX Receives Approval for NYSE Compliance Plan
- Compliance Plan Approval: BiomX received notification from NYSE on June 10, 2026, confirming acceptance of its compliance plan, which is set to last until September 25, 2027, aimed at regaining compliance with NYSE listing standards and ensuring continued trading of its stock on NYSE American.
- Financial Warning: The company reported a stockholders' equity deficit of $1.302 million as of December 31, 2025, alongside ongoing losses over the past five fiscal years, prompting NYSE to require corrective actions for compliance restoration.
- Periodic Review Mechanism: During the implementation of the compliance plan, NYSE will conduct periodic reviews of BiomX's compliance, which not only tests the company's management capabilities but also impacts its future market performance and investor confidence.
- Business Operations Unaffected: Despite facing compliance challenges, BiomX stated that its business operations and reporting obligations to the SEC will remain unaffected, indicating that the company will maintain normal operations while addressing compliance issues.
See More
BiomX Unveils New Insights on Security Industry
- Industry Transformation: BiomX's Zorronet CEO Idan Wasserman emphasizes in a new review that the future of AI security systems will hinge not on the number of surveillance devices but on their ability to understand information, thereby enhancing responses to complex security environments.
- Cultural Context Understanding: The review highlights that AI systems must grasp cultural and situational contexts to accurately assess the significance of behaviors, preventing misjudgments and ensuring security teams can swiftly respond to genuine threats, thus improving overall security efficiency.
- Increased Control Room Burden: As information sources diversify, traditional control rooms are under growing pressure; Wasserman argues that next-generation security platforms must support real-time prioritization and decision-making to tackle complex security challenges effectively.
- Innovative Technology Integration: Zorronet is developing an Autonomous Command Center designed to unify cameras, sensors, drones, and AI agents into a cohesive real-time operational picture, thereby enhancing the speed and coordination of responses for security and operations teams.
See More
BiomX Appoints Prof. Gabby Sarusi as Strategic Advisor
- Strategic Advisor Appointment: BiomX has appointed Prof. Gabby Sarusi as a Strategic Advisor, leveraging his extensive experience in technology development and strategic planning to enhance the company's expansion in defense and security sectors, thereby improving its market competitiveness.
- Industry Background: Prof. Sarusi brings 17 years of senior leadership experience from Elbit Systems Electro-Optics, where he was involved in developing technologies such as satellite cameras and infrared detectors, providing valuable industry insights for BiomX's integration in critical infrastructure and first-response sectors.
- Market Alignment: Prof. Sarusi noted that the defense and security market is moving towards earlier threat detection and faster response capabilities, aligning perfectly with BiomX's technologies, which are expected to enhance the company's ability to address emerging threats effectively.
- Academic and Practical Integration: With dual bachelor's degrees in Nuclear Engineering and Materials Engineering, along with a master's and Ph.D. in Electrical Engineering, and research experience at NASA and AT&T Bell Labs, Prof. Sarusi's academic background will strongly support BiomX's technological innovation and market application.
See More
BiomX Expands Zorronet's Autonomous C5ISR Suite for Secure Deployments
- Growing Market Demand: BiomX has announced the expansion of Zorronet's autonomous C5ISR suite to support fully secure local, hybrid, and closed-loop deployments in defense, security, and critical infrastructure, reflecting the increasing demand for autonomous command-and-control systems, with the market projected to reach $189 billion by 2030.
- Data Security Protection: The new system allows organizations to run the complete Zorronet C5ISR suite within protected infrastructure, avoiding reliance on public cloud, thereby meeting regulatory and cybersecurity requirements and ensuring that sensitive data remains shielded from public networks.
- Real-Time Response Capability: Zorronet's architecture supports local AI processing and edge computing, enabling real-time inference within restricted networks, which helps teams swiftly transition from detection to execution, significantly enhancing response speed and operational efficiency.
- Integration Advantages: The system can integrate with existing security devices, including cameras, sensors, and drones, forming a unified C5ISR suite that transforms complex security data into clear real-time alerts and commands, thereby improving operational efficiency.
See More
BiomX Successfully Deploys Zorronet with Israel Railways
- Successful Pilot Project: Israel Railways invested approximately NIS 800,000 in the Zorronet pilot project, achieving a 98% success rate in preventing wildlife from entering railway tracks, thereby preserving ecological corridors and reducing infrastructure damage.
- Technical Deployment Details: Zorronet will install 15 AI-enabled alert stations capable of detecting and deterring animals within a 120-meter range, with an initial 12-month agreement and plans for additional stations to enhance railway safety.
- Real-Time Monitoring Capability: The system integrates camera analytics and AI technology to detect human and animal approaches to tracks in real time, quickly assess risks, and trigger alerts, ensuring the safety and efficiency of railway operations.
- Strategic Partnership Outlook: The collaboration with Israel Railways validates Zorronet's position as a technology provider for national infrastructure, with potential for broader deployment across the railway network, further enhancing its competitive edge in the market.
See More
BiomX Acquires DFSL to Expand into Defense Sector
- Acquisition of Control: BiomX Inc. announced the acquisition of a controlling interest in DFSL as part of its expansion into the defense sector, with the deal involving cash payment, an unsecured convertible note, and warrants exercisable at $12 per share, indicating a strategic move into new markets.
- Technology Integration: This month, BiomX also acquired Zorronet, integrating its AI-driven platform for fast and accurate target detection, which reduces false alarms and enhances the company's competitiveness in defense technology.
- DFSL's Expertise: DFSL specializes in hardware and signal processing, having developed LADAR (laser detection and ranging) technology for real-time tracking of aerial or ground targets, thereby strengthening BiomX's technical capabilities in defense applications.
- Stock Price Fluctuation: BiomX closed at $2.63 on Monday, down 9%, but shares rebounded to $2.68 in the overnight market, up 1.90%, reflecting cautious market sentiment regarding the acquisition news.
See More
